Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2017—Sarah Cannon, the cancer institute of Hospital Corporation of America, announced that Genospace LLC, a cloud-based software company focused on advancing personalized medicine, will merge with its organization and become a wholly owned subsidiary. By joining forces, Sarah Cannon and Genospace will harness and use molecular profiling data to more effectively match cancer patients to cutting-edge therapies in clinical trials.
April 2017—Singulex has entered into a strategic collaboration with Qiagen to develop companion diagnostics. Through the collaboration, Qiagen will have access to Singulex’s Single Molecule Counting (SMC) immunodiagnostic platform, adding immunoassay capabilities to Qiagen’s existing molecular testing services for the development of companion diagnostics.
March 2017—Streck’s CE-marked antibiotic resistance monitoring and detection (ARM-D) kits are now available. The Streck ARM-D kits, AmpC and β-lactamase, are multiplex real-time PCR reagents for the detection of more than 450 β-lactamase gene targets.
March 2017—LGC Maine Standards added rheumatoid factor to its Validate SP2 calibration verification/linearity test kit. Validate SP2 evaluates albumin, C-reactive protein, haptoglobin, prealbumin, and rheumatoid factor in a human serum base. Each kit is prepared using the CLSI-recommended “equal delta” method for linearity testing and is liquid, ready to use.
March 2017—Qiagen announced it submitted its QuantiFeron-TB Gold Plus, the fourth generation of the modern blood test for detecting tuberculosis infection, for premarket approval by the Food and Drug Administration.
March 2017—Ortho Clinical Diagnostics has submitted a premarket approval application to the U.S. Food and Drug Administration for the Vitros Immunodiagnostic Products HIV Combo Assay for use on the Vitros 3600 immunodiagnostic system.
March 2017—Streck’s Para 12 Extend, a hematology control with three distinct populations of lymphocytes, mononuclears, and granulocytes, is now assayed for the Mindray BC-3600. Varying percentages are also offered in the low abnormal, normal, and high abnormal levels to test the accuracy and precision of the reported white cell populations.
March 2017—LGC Maine Standards’ Validate D-Dimer calibration verification/linearity test kit received FDA 510(k) clearance for use on Stago STA-R Evolution analyzers.
March 2017—Abbott announced its Alinity ci-series instruments for clinical chemistry and immunoassay diagnostics have obtained the CE mark and are available in Europe and other countries that recognize the CE mark.
March 2017—Sarstedt introduced a 90 mL screw cap urine cup with a tri-sensory proof-of-closure system. Dual click sounds can be heard and two bumps felt as the cap reaches the correct sealed position on the cup.
